Abstract:Pulmonary arterial hypertension (PAH) is a rare and critical cardiovascular disease characterized by increased pulmonary vascular resistance, lesions in the pulmonary arterioles, and a subsequent rise in the right ventricular load, which inevitably leads to right heart failure. Unfortunately, patients with PAH have a poor prognosis, with a median survival time of 2.8 years under traditional drug therapy when there are no targeted pharmaceuticals, earning it the reputation of being a cancer of the cardiovascular system. Patients with PAH face significant challenges. They usually show nonspecific clinical manifestations in the early stages, which often leads to delayed diagnosis and treatment. The majority of the population with PAH in China are young and middle-aged females. Apart from physical difficulties, these patients may have a poor quality of life despite adequate drug treatment. Many patients experience anxiety, depression, or other psychological disorders. These burdens not only affect patients but also place immense strain on their families and society. The current 5-year survival rate for critically severe patients with PAH receiving optimal drug treatment is only 33.3%. To address these challenges, risk assessment plays a crucial role in guiding the clinicians’ decision-making processes, treatment evaluation, and prognosis prediction for patients with PAH. However, establishing effective risk stratification requires extensive clinical research. High-level clinical research can serve as a means of solving clinical problems and we can gain insights into the process and methods involved. The Chinese PAH cohort represents a unique opportunity to study international experiences in the development of a risk stratification system suitable for the Chinese population. By systematically outlining the development of PAH from its first description as a disease, which garnered attention from the World Health Organization, we appreciate the importance of conducting clinical research that has helped enhance our understanding of this disease. Establishing prognostic prediction equations through clinical studies and conducting international research on risk stratification in the era of targeted drug therapy are vital steps for continuously updating risk stratification guidelines and treatment concepts. The development of high-level clinical research in China can draw inspiration from these processes. By leveraging lessons learned from international experiences, we can pave the way for advancements in PAH research within the country. This included addressing the current application status and challenges faced in the implementation of risk stratification for PAH in China. Future research should focus on refining the risk stratification methods, exploring innovative diagnostic techniques, and identifying novel treatment approaches for PAH. By continuously enhancing our understanding of this complex disease, we can improve patient outcomes and alleviate the burden on individuals, families, and the society as a whole. In conclusion, PAH presents significant challenges in diagnosis, treatment, and risk assessment. By delving into high-level clinical research to address these challenges, we can pave the way for improved management strategies and better outcomes for patients with this devastating condition. Through international collaborations and tailored approaches for the Chinese population, we can strive towards more accurate risk stratification and ultimately enhance the overall care provided to individuals with PAH.

Characteristics, treatments and survival of pulmonary arterial hypertension associated with congenital heart disease in China: Insights from a national multicenter prospective registry

Characteristics, Long-term Survival, and Risk Assessment of Pediatric Pulmonary Arterial Hypertension in China Insights From a National Multicenter Prospective Registry

Characteristics, Long-term Survival, and Risk Assessment of Pediatric Pulmonary Arterial Hypertension in China

Paediatric Pulmonary Arterial Hypertension in China During 2006-18: Insights from a Longitudinal Registry Study

Congenital heart disease with pulmonary artery hypertension in an Asian cohort-initial report from TACHYON (TAiwan congenital heart disease associated with pulmonarY arterial hypertension) registry

Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension.

Pulmonary Arterial Hypertension after Operation for Congenital Heart Disease: Analysis of Baseline Clinical Characteristics of 122 Chinese Patients

Characteristics and long‐term survival of patients with chronic thromboembolic pulmonary hypertension in China

Long-term Survival of Patients with Repaired Congenital Heart Disease Associated Pulmonary Arterial Hypertension (CHD-PAH) in the Modern Management Era

Characteristics, goal‐oriented treatments and survival of pulmonary arterial hypertension in China: Insights from a national multicentre prospective registry

High-level clinical research promotes the development of risk stratification for pulmonary arterial hypertension

Idiopathic Pulmonary Arterial Hypertension and Pulmonary Arterial Hypertension Associated with Congenital Heart Disease in Chinese Children: Similarities, Differences, and Prognostic Factors

Long-term postoperative outcome of congenital heart defects with severe pulmonary hypertension in children

10-Year Survival of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease: Insights from a Multicentre PAH Registry

Differences in right ventricular function and response to targeted therapy between patients with IPAH and PAH-CHD

Baseline Characteristics And Survival Of Chinese Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension

Pulmonary arterial hypertension associated with congenital heart disease in children: clinical characterisation, outcomes and changes in demographics over time

Clinical Characteristics and Factors Associated with Disease Progression in Chinese Patients with Connective Tissue Disease and Pulmonary Arterial Hypertension

Survival of Chinese Patients with Pulmonary Arterial Hypertension in the Modern Treatment Era

Surgical Treatment on Congenital Heart Disease with Severe Pulmonary Hypertension

Echocardiographic Insights into Pulmonary Arterial Hypertension: the Advantage of Congenital Heart Disease Patients